Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with certain types of large B-cell lymphoma, confirmed by a tissue biopsy, including specific subtypes such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma grade 3B, high-grade B-cell lymphoma, or transformed follicular lymphoma.
• People whose lymphoma came back or stopped responding after their first round of treatment, where that treatment included specific types of drugs (an anti-CD20 antibody and an anthracycline chemotherapy drug).
• People who have at least one measurable or detectable area of lymphoma that can be tracked using standard lymphoma assessment guidelines.
• People whose lymphoma has not spread to the brain or spinal cord, with no known or suspected involvement of the central nervous system.
• People who have waited long enough since their last cancer treatment — either more than 2 weeks or more than 5 times the drug's half-life, whichever is shorter.
• People aged 18 or older.
• People who are well enough to carry out basic daily activities, based on a standard performance scale rated 0 to 2 (confirm with trial site).
• People expected to survive for at least 3 months.
• Women who could become pregnant must have a negative pregnancy test within 7 days before the first dose, and both women who could become pregnant and men whose partners could become pregnant must agree to use effective contraception from the time of signing the consent form until 6 months after the last dose.
• People who are able to follow the trial's requirements as assessed by the trial team.
• People who have voluntarily agreed to take part and have signed an informed consent form.

Who may not be able to join:

• People who have had another cancer in the past 5 years, except for certain skin cancers or early-stage cancers that were fully treated (such as basal cell skin cancer, squamous cell skin cancer, early breast cancer in situ, or early cervical cancer in situ).
• People who have previously had a stem cell transplant, either using their own cells or from a donor.
• People with a history of Richter transformation (a condition where a slower-growing blood cancer changes into a more aggressive type) (confirm with trial site).
• People who have already received more than one round of systemic cancer treatment.
• People who have previously been treated with a type of drug called a PI3K inhibitor.
• People with a known allergy or sensitivity to the trial drugs.
• People who currently have an active infection — such as bacterial, viral, or fungal — that requires treatment, including pneumonia.
• People who need to take high-dose steroid tablets or other immune-suppressing medications on an ongoing basis (those using steroid inhalers or creams may still be considered).
• People who have difficulty taking oral medications, for example due to trouble swallowing, ongoing severe diarrhoea, or bowel blockage.
• People with a history of substance misuse or mental health conditions that are not well managed.
• People with uncontrolled high blood pressure, significant heart conditions (such as heart attack history, abnormal heart rhythms, or moderate-to-severe heart failure), or serious lung conditions that significantly reduce lung function.
• People with a history of lung inflammation caused by COVID-19.
• People with serious liver disease, including advanced cirrhosis or significant known liver conditions.
• People whose kidneys have failed and who need dialysis.
• People with uncontrolled fluid build-up around the lungs, heart, or abdomen that requires repeated draining.
• People with significant amounts of protein detected in their urine (confirmed by testing).
• People with active autoimmune diseases (such as lupus, rheumatoid arthritis, or inflammatory bowel disease) or those considered at high risk of these conditions — though people with stable autoimmune thyroid disease requiring only hormone replacement may be considered.
• People who have a known HIV infection or AIDS diagnosis.
• Women who are pregnant, breastfeeding, or who test positive for pregnancy at the start of the trial.
• People with other health conditions that, in the trial doctor's judgement, could put them at serious risk or prevent them from completing the trial.

Important: Always verify eligibility with the trial site directly before applying.